Peisong Ma on GRK5 Polymorphism Affecting Platelets
Peisong Ma, Associate Professor at Thomas Jefferson University, shared on LinkedIn:
”Excited to share that our latest manuscript, “Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk,” is now published in the Blood Journal (online first).
In this study, we identify GRK5 as a previously unrecognized regulator of platelet PAR1 signaling and provide the first experimental evidence linking this common A→G variant to enhanced thrombin/PAR1 signaling and increased thrombus formation in vivo.
Using human GG donor platelets, iPSC-derived megakaryocytes, GRK5 inhibition, a humanized mouse model, and two preclinical models, our work connects human genetics → platelet GPCR regulation → thrombotic disease. These findings highlight GRK5 as a potential contributor to stroke and venous thromboembolism risk, with implications for future thrombophilia assessment.
Huge congratulations to my PhD students Yanki Yarman and Xuefei Zhao, and sincere thanks to our collaborators at Jefferson, CHOP, Cambridge, Mount Sinai, UPenn, and Purdue.”
Read the full article here.
Article: Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk
Authors: Yanki Yarman, Xuefei Zhao, Hyunsook Ahn, Hannah A Thomson, Amrita Sarkar, Tian Yuan, Meghan E. Roberts, Jeremy Wurtzel, Scott L Diamond, John J.G Tesmer, Deborah L French, Maurizio Tomaiuolo, Ernest Turro, William Astle, Lawrence E. Goldfinger, Steven E. McKenzie, Jeffrey Benovic, Timothy J. Stalker, Mortimer Poncz, Peisong Ma
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring